Sammyall, thanks for the reminder, but you haven't made me sleep any easier. So PAR's patents are for BME, not OA. Does that mean anyone can treat OA with PPS without infringing the patent? Can Bene sell PPS to a competitor if it's for 'pain relief'? Can a Big Pharma company run a combined safety-efficacy trial using the Indian PPS for OA and have a drug on the market 2 years after Zilosul without patent infringement?
This is the problem with relying on compounds that are off-patent.
Paradigm Ip Patents/ Trademarks, page-8
-
- There are more pages in this discussion • 20 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.8¢ |
Change
0.003(0.85%) |
Mkt cap ! $103.1M | |||
| Open | High | Low | Value | Volume |
| 30.0¢ | 30.0¢ | 29.5¢ | $34.53K | 115.5K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 40539 | 29.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 28.5¢ | 56 | 1 |
View Market Depth
| Last trade - 15.59pm 22/07/2024 (20 minute delay) ? |
| PAR (ASX) Chart |